Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

PRNewswire

– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations –

– Findings From In-Depth Qualitative Patient Interviews on the Burden of Narcolepsy Will Also Be Presented –

DUBLIN, May 28, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.

The company will present two posters during a late-breaking abstract session:

• Data from the full cohort (n=10)1 of patients with narcolepsy type 1 (NT1) from the phase 1b, proof-of-concept study evaluating single dose oral administration of ALKS 2680. Safety results and pharmacodynamic efficacy assessments evaluating objective (Maintenance of Wakefulness Test [MWT]) and subjective patient-reported (Karolinska Sleepiness Scale [KSS]) measures of sleepiness will be presented.
• Study design and methods for the Vibrance-1 study, a recently initiated phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with NT1.

In addition, findings from in-depth, qualitative interviews with patients with NT1 (n=12) and narcolepsy type 2 (NT2) (n=10) will be presented. During the 60-minute interviews, participants described the impact and burden of disease on many facets of their lives, including work and school activities, mental health, activities of daily living and relationships.